---
layout: default
title: Abies Balsamea Leaf Oil Acer Pensylvanicum Whole A
parent: 僅模型預測 (L5)
nav_order: 46
evidence_level: L5
indication_count: 0
---

# Abies Balsamea Leaf Oil Acer Pensylvanicum Whole A
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Allergen-Corticotropin Mixture: Insufficient Data for Repurposing Prediction

## One-Sentence Summary

This product is a complex multi-ingredient mixture combining corticotropin (ACTH), histamine dihydrochloride, and over a dozen botanical allergens and pollen extracts — characteristics consistent with an allergy immunotherapy or diagnostic formulation.
The TxGNN model was **unable to generate any repurposing predictions** for this candidate, as the product has no registered DrugBank ID, no mapped original indications, and no presence in the US regulatory database.
Without a prediction target, a formal repurposing evaluation cannot proceed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established (no regulatory approvals on record) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only, no actual studies (and prediction is absent) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No repurposing prediction is available for this product, so a mechanistic rationale cannot be constructed in the standard sense. The following is a factual characterization of the product to aid downstream decision-making.

The mixture contains **corticotropin (ACTH)**, a pituitary peptide hormone that stimulates the adrenal cortex to secrete glucocorticoids. Corticotropin as a standalone agent has established indications (e.g., infantile spasms, multiple sclerosis relapse), and a pharmacological mechanism exists. However, in this product it is combined with substances such as **histamine dihydrochloride** and a large panel of **environmental allergens** (tree pollens from *Betula*, *Quercus*, *Juniperus*, *Picea*, *Pinus*, *Populus*, *Pseudotsuga*, *Fraxinus*, *Hesperocyparis*; bark/wood extracts from *Alnus*, *Carya*, *Biancaea sappan*; and animal-derived materials including beef liver and *Sus scrofa* adrenal gland). This composition is most consistent with a **multi-allergen immunotherapy or allergy desensitization formulation**, or potentially a homeopathic preparation.

Because the product is a fixed-dose combination of biologically heterogeneous materials — not a single chemical entity — standard TxGNN knowledge-graph mapping (which operates on individual DrugBank nodes) cannot generate a valid repurposing score. The pipeline correctly returned no predictions.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this multi-component product as a unified entity.

---

## Literature Evidence

Currently no related literature available for this multi-component product as a unified entity.

---

## US Market Information

No US regulatory authorizations on record for this product.

---

## Safety Considerations

Please refer to the package insert for safety information. No safety data (warnings, contraindications, or drug interaction records) was retrievable for this product via the queried sources.

> **Note on CORTICOTROPIN component**: Corticotropin as a standalone agent carries known warnings including immunosuppression, adrenal suppression, and risks in patients with active infections. If this product is evaluated further, the safety profile of corticotropin should be consulted separately from its single-agent package insert.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This product cannot be assessed through the standard TxGNN repurposing pipeline because it is a multi-ingredient mixture with no DrugBank ID, no mapped original indications, no TxGNN prediction, and no regulatory history in any queried jurisdiction. A Hold is appropriate until the product's identity and regulatory standing are clarified.

**To proceed, the following is needed:**

- **Product identity clarification**: Determine whether this is (a) a defined pharmaceutical product with a specific NDA/approval, (b) a homeopathic preparation, or (c) an allergy immunotherapy diagnostic kit. Each category requires a different evaluation pathway.
- **DrugBank mapping**: If corticotropin is the intended active ingredient for repurposing analysis, re-run the pipeline using corticotropin's DrugBank ID (DB01285) as the sole query target.
- **Original indication documentation**: Obtain the prescribing information or regulatory filing to establish what clinical claim, if any, this combination is approved or intended for.
- **MOA clarification**: Determine which ingredient(s) are considered pharmacologically active versus inert carriers or allergen antigens.
- **Safety data retrieval**: Download the TFDA or FDA package insert (if available) to complete the DG001 and DG002 data gaps flagged in the Evidence Pack.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

